Servier to Acquire Edgewise Therapeutics' Muscular Dystrophy Assets for Up to $2.65B

Why It Matters

The acquisition gives Servier a rare‑disease asset with unmet market potential, while allowing Edgewise to concentrate on higher‑margin cardiac programs, reshaping both companies' growth trajectories.

Key Takeaways

• Servier pays $1.55B upfront for Edgewise's muscular dystrophy assets
• Sevasemten in Phase 3 for Becker, Phase 2 for Duchenne
• Milestone payments could add up to $1.1B for Edgewise
• Servier aims for $11.6B revenue by 2030, expanding neurology
• Edgewise redirects focus to cardiovascular pipeline after sale

Pulse Analysis

French drugmaker Servier announced a $1.55 billion upfront purchase of Edgewise Therapeutics’ muscular‑dystrophy program, with up to $1.1 billion in contingent milestones. The deal marks Servier’s first major move into neuromuscular disorders, complementing its $2.5 billion oncology franchise and recent $2.4 billion acquisition of Day One Biopharma. By adding an oral myosin inhibitor to its pipeline, Servier is positioning itself for the 2030 ambition to lift total revenue to roughly $11.6 billion, a target that hinges on expanding beyond cancer into rare neurological diseases.

Sevasemten, the asset at the center of the transaction, blocks fast‑skeletal myosin to curb the hyper‑contraction that accelerates muscle loss in Becker and Duchenne muscular dystrophy. The drug is in Phase 3 for Becker—a disease with no approved therapy—and Phase 2 for Duchenne, where several exon‑skipping agents already exist. If the Phase 3 read‑out confirms efficacy, sevasemten could capture a multi‑hundred‑million niche, especially given its oral administration and cardiac‑sparing profile, differentiating it from injectable gene‑based treatments.

With the muscular‑dystrophy business sold, Edgewise will concentrate on its cardiovascular portfolio, including EDG‑7500 for hypertrophic cardiomyopathy and early‑stage candidates EDG‑15400 and EDG‑003. The upfront cash is earmarked to fund EDG‑7500 through a potential approval, reducing financing risk for shareholders. Analysts view the transaction as a win‑win: Servier gains a rare‑disease foothold while Edgewise clears valuation uncertainty and redirects capital to a market where it sees higher upside. The deal also underscores a broader industry trend of larger pharma firms buying niche, late‑stage assets to diversify revenue streams.

Deal Summary

French pharma Servier announced the acquisition of Edgewise Therapeutics' muscular dystrophy assets for $1.55 billion upfront, with up to $1.1 billion in milestone payments, bringing total potential value to $2.65 billion. The deal includes the oral small‑molecule sevasemten, currently in Phase 3 for Becker muscular dystrophy and Phase 2 for Duchenne muscular dystrophy. The transaction is expected to close in the third quarter of 2026.